Objective To explore the clinical effects of albumin-bound paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer.Methods A total of 102 patients with advanced non-small cell lung cancer treated in our hospital between January 2018 and January 2020 were selected and divided into two groups according to the random number table method, with 51 cases in each group. Patients in control group were given paclitaxel combined with carboplatin, and those in observation group were given albumin-bound paclitaxel combined with carboplatin. The short-term efficacy and the incidence of adverse reactions were compared between the two groups.Results The short-term effect of the observation group was better than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the response rate of squamous cell carcinoma between the two groups (P>0.05). In addition, there was no significant difference in the incidence of grade 1~4 adverse reactions between the two groups, nor difference in the incidence of grade 3~4 adverse reactions (P>0.05).Conclusion Albumin-bound paclitaxel combined with carboplatin had good clinical effects in the treatment of patients with advanced non-small cell lung cancer. Its toxic and side effects were light and tolerable, and it was worth promoting.